Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Capital Reinvestment Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Capital Reinvestment Ratio of 7.61x as of December 2023, meaning it reinvests 8% of its operating cash flow (CN¥90.45 Million) in capital expenditures (CN¥688.60 Million). See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Capital Reinvestment Ratio (2019–2023)
This chart tracks Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2023)
Year-by-year Capital Reinvestment Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2023. For live market cap and broader valuation context, see 301096 market cap.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 7.61x | CN¥90.45 Million | CN¥688.60 Million | ▲ +233.8% |
| 2022 | 2.28x | CN¥259.41 Million | CN¥591.58 Million | ▲ +33.5% |
| 2021 | 1.71x | CN¥145.42 Million | CN¥248.45 Million | ▼ -63.6% |
| 2020 | 4.69x | CN¥54.36 Million | CN¥255.12 Million | ▲ +213.6% |
| 2019 | 1.50x | CN¥71.47 Million | CN¥106.95 Million | — |